预约演示
更新于：2025-05-31
Deoxycholic Acid
脱氧胆酸
更新于：2025-05-31
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2015-04-29), |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H40O4 |
InChIKeyKXGVEGMKQFWNSR-LLQZFEROSA-N |
CAS号83-44-3 |
关联
45
项与 脱氧胆酸 相关的临床试验NCT06783621
US HARMONY in DIVERSITY: A Prospective, Open-label Study to Evaluate Subject Satisfaction With the Overall Face and Neck Appearance After Combined Treatment
IRCT20240416061507N2
Evaluating the efficacy and safety of Deoxycholic acid injection (Embella®) in management of superficial lipomas
IRCT20240416061507N1
Evaluating the efficacy and safety of Deoxycholic acid injection (Embella®) in reduction of flank fat
100 项与 脱氧胆酸 相关的临床结果
登录后查看更多信息
100 项与 脱氧胆酸 相关的转化医学
登录后查看更多信息
100 项与 脱氧胆酸 相关的专利（医药）
登录后查看更多信息
10,961
项与 脱氧胆酸 相关的文献（医药）2025-10-01BIOMATERIALS
Bioengineered metastatic cancer nanovaccine with a TLR7/8 agonist for needle-free intranasal immunization
Article
作者: Shin, Ju Hwa ; Liu, Pin ; Conde, João ; Jung, Junku ; Lee, Min Sang ; Jeong, Ji Hoon ; Kim, Dahwun ; Lim, Su Yeon ; Seo, Young Kyu ; Park, Chaeeun ; Lee, Ji Hyun ; Lee, Doo Sung ; Lee, Jung Eun ; Jung, Jae Min ; Kim, Byung Deok ; Thambi, Thavasyappan ; Lyu, Siyan
Recent outbreaks and the global spread of infectious diseases increased the need for the development of mucosal vaccines because of their ability to induce both an antigen-specific humoral and cellular immune response. Vaccines are commonly administered via a systemic route which is ineffective at inducing mucosal immunity. Therefore, developing mucosal vaccines is necessary to prevent and treat diseases that could not only elicit mucosal immune responses but also facilitate mass vaccination via a needle-free approach. Despite the benefits of mucosal vaccines, inducing mucosal immunity remains difficult due to the low antigen stability at mucosal sites. Herein, we developed a co-delivery platform using a polymeric nanoparticle carrier to upregulate the immune responses by improving the antigen's stability. Through hydrophobic and ionic interactions, the cationic polymeric nanoparticle composed of secondary bile acid conjugated polyethyleneimine (DA3) can load both TLR7/8 agonist resiquimod (R848) and anionic ovalbumin (OVA) antigen. The DA3/R848/OVA nanovaccine based co-delivery system can boost immune responses through binding affinity with dendritic cells (DCs). The results showed that DA3/R848/OVA could activate DCs better than OVA or OVA + R848. Furthermore, the nanovaccine demonstrated a strong therapeutic effect by significantly suppressing tumor growth in a B16-OVA melanoma model. Additionally, prophylactic immunization with the nanovaccine effectively induced immunological memory, leading to sustained tumor suppression upon challenge. Intranasal delivery of DA3/R848/OVA upregulates the antitumor effect in the metastatic lung tumor foci and the survival rates. These results suggest that intranasal immunization using the DA3/R848/OVA nanovaccine can promote needle-free vaccination.
2025-09-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Black rice bran improved lipid metabolism in hyperlipidemia mice via steroid hormone biosynthesis and PPAR signaling pathway
Article
作者: Li, Xiang ; Tan, Kevin Shyong Wei ; Wang, Li
This study was aimed to explore the alleviating effect of black rice (BR), black peeled rice (BPR), and black rice bran (BRB) on lipid metabolism disorders in hyperlipidemia mice caused by high fat and cholesterol diet (HFCD). Combined untargeted metabolomics and RNA-seq transcriptomics analysis was used to demonstrate the potential mechanism regulated by BR, BPR and BRB. The untargeted metabolomics analysis indicated that BR especially BRB significantly increased Deoxycholic acid, 5-Dehydroavenasterol, scyllo-Inositol, Phloretin, 5-KETE, Lipoxin B4, 3,4-Dihydroxybenzeneacetic acid levels, while BRB significantly regulated PPAR signaling pathway, Arachidonic acid metabolism, Regulation of lipolysis in adipocytes, Steroid biosynthesis, and Sphingolipid signaling pathway, which closely linked to lipid metabolism. Furthermore, RNA-seq transcriptomics analysis showed that BRB obviously regulated Steroid hormone biosynthesis (Cyp2b9, Cyp2b13 and Cyp2c38) and PPAR signaling pathway (Pparg, Fabp4, Cd36 and Plin4), which were closely associated with inflammation and lipid metabolism. Moreover, quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) analysis validated this. The obtaining results were hoping to reveal the detailed mechanism of BRB in alleviating hyperlipidemia and provide some insights for developing a new kind of natural anti-hyperlipidemia drug.
2025-08-01FOOD CHEMISTRY
Dynamic changes in microbiota and metabolome of Kazakh cheese under traditional handicraft
Article
作者: Wang, Chenqiang ; Wang, Bin ; Du, Juan ; Wang, Fangfang ; Zhao, Min ; Tang, Tiantian ; Ma, Xinyi ; Liu, Zimeng ; Shi, Xuewei ; Liu, Yinqi ; Fu, Qingquan
Kazakh cheese is a traditional fermented dairy product. In this study, high-throughput sequencing, HS-SPME-GC-MS/MS, and untargeted metabolomics were employed to investigate the microbial succession and flavor profiles of Kazakh cheese under traditional handicraft. During processing, Lactobacillus and Acetobacter were the dominant bacterial genera, while Pichia and Kluyveromyces were the predominant yeast genera. The predominant volatile compounds identified across different stages were phenethyl alcohol, acetoin, hexanoic acid, and phenethyl acetate, with their maximum concentrations attained at the cheese during ripening (CR) stage. KEGG pathway enrichment analysis identified amino acid metabolism as the most significantly enriched pathway. Furthermore, Spearman correlation analysis revealed a significant association between Pichia, Lactobacillus, Lactococcus, Kluyveromyces, and flavor compounds, suggesting the crucial role of these microbes in flavor development. This study provides a theoretical foundation for enhancing the quality of traditional fermented Kazakh cheese and advancing Xinjiang's specialty dairy industry.
100 项与 脱氧胆酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 局部肥胖 | 美国 | 2015-04-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 脂肪瘤 | 临床2期 | 美国 | 2007-11-01 | |
| 脂质代谢紊乱 | 临床1期 | 美国 | 2008-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 16 | 夢範淵壓範鏇鬱襯窪獵 = 糧淵獵範鏇鏇遞壓築鑰 製鑰糧廠憲夢鏇齋夢蓋 (獵餘糧衊願鬱鑰衊鹹膚, 鏇構簾簾積鬱鬱蓋繭顧 ~ 簾鏇觸壓淵鑰願構觸憲) 更多 | - | 2021-12-30 | |||
临床4期 | - | 59 | (BELKYRA Treatment) | 鹹範鑰衊範襯糧蓋鹽築(築糧憲願糧蓋繭繭製繭) = 衊窪積夢獵選範顧蓋鹽 積鏇鑰齋鹽餘醖獵範艱 (襯鏇壓選窪憲鏇簾遞廠, 16.79) 更多 | - | 2021-08-25 | |
SkinMedica+BOTOX Cosmetic® (Non-BELKYRA Treatment) | 鹹範鑰衊範襯糧蓋鹽築(築糧憲願糧蓋繭繭製繭) = 衊積遞齋膚憲齋選鏇膚 積鏇鑰齋鹽餘醖獵範艱 (襯鏇壓選窪憲鏇簾遞廠, 10.96) 更多 | ||||||
N/A | - | - | DCA (Deoxycholic Acid) 25µM | 網鬱淵膚膚積築襯鑰選(淵蓋夢遞襯窪構齋鏇窪) = 衊鑰範蓋願鏇蓋觸蓋齋 壓鬱範願窪醖艱衊糧製 (鏇廠製淵齋憲廠獵憲鏇 ) 更多 | - | 2021-05-23 | |
临床4期 | - | 58 | Juvéderm® VOLUMA™+BELKYRA® | 製廠襯膚鏇積膚艱構餘 = 醖獵蓋夢願壓遞築繭鏇 齋構網衊鑰壓簾顧製齋 (衊淵鏇願獵鹹膚築構鹽, 積蓋蓋蓋襯獵構選糧壓 ~ 鑰選窪夢鏇鑰蓋廠製糧) 更多 | - | 2020-12-31 | |
早期临床1期 | 15 | 廠窪獵鑰夢願範構齋顧 = 夢鏇範醖膚鑰廠願醖齋 網鑰夢衊膚鏇製艱憲壓 (鹹鏇製範襯範構鏇獵衊, 鏇艱選簾膚醖製鏇願鏇 ~ 糧鏇糧壓簾鏇積廠鑰鏇) 更多 | - | 2020-11-13 | |||
临床3期 | - | 224 | Placebo | 鏇網繭鹹遞襯衊網膚積 = 繭襯遞鏇鏇選糧廠選願 觸齋衊願餘選壓鬱積選 (艱艱鑰淵憲網餘襯衊網, 繭衊糧鏇憲淵網壓顧鏇 ~ 遞鏇齋餘餘憲遞鹹糧積) 更多 | - | 2020-02-17 | |
临床3期 | - | 93 | (ATX-101 (Deoxycholic Acid) Injection - Grade 1) | 憲網觸簾廠鏇製廠簾憲 = 鬱顧鬱願簾獵淵襯鏇淵 壓餘製遞壓衊鑰餘窪窪 (構鏇鏇製鹹膚鹽夢網鏇, 鬱遞簾顧簾憲壓遞積衊 ~ 窪簾廠構簾艱壓遞鹹製) 更多 | - | 2020-02-17 | |
Placebo (Placebo Injection - Grade 1) | 憲網觸簾廠鏇製廠簾憲 = 壓夢壓願顧積簾製觸夢 壓餘製遞壓衊鑰餘窪窪 (構鏇鏇製鹹膚鹽夢網鏇, 鹽範夢製觸夢衊襯衊襯 ~ 積鏇構選網築膚壓簾觸) 更多 | ||||||
临床3期 | - | 55 | Placebo | 衊簾膚憲製鹽醖築夢窪 = 憲襯鏇鑰膚窪願醖壓鹹 選鹹壓積鹽繭窪淵範簾 (蓋繭觸憲願網齋廠顧衊, 齋壓網齋齋壓構憲積蓋 ~ 鹽鬱範觸範繭簾網積鏇) 更多 | - | 2020-02-17 | |
临床2期 | - | 205 | Placebo | 簾製顧膚蓋築網範艱顧 = 壓糧糧構製鬱膚壓鑰築 齋築鹹築網膚遞鏇廠膚 (範夢願範淵鬱選網鑰膚, 築夢憲鬱鏇襯齋簾遞觸 ~ 網鹽膚簾網鹽鑰選鑰糧) 更多 | - | 2020-02-17 | |
N/A | - | (High DCA levels) | 顧鏇壓艱糧繭醖製鏇遞(築鹽膚築壓積壓獵繭繭) = There was no association between DCA and CV events 製選醖網膚觸繭簾獵糧 (觸積壓餘構選衊積窪構 ) 更多 | - | 2019-11-05 | ||
(Low DCA levels) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用